Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Peeling paint, shoddy cleanups among issues at U.S. plant making J&J COVID-19 vaccine: FDA

04/21/2021 | 11:14pm EDT
FILE PHOTO: Vials labelled

(Reuters) - A U.S. plant that was making Johnson & Johnson's COVID-19 vaccine must fix a long list of problems including peeling paint, shoddy cleanups, and poorly-trained staff to resume operation, according to a highly critical report by the Food and Drug Administration.

Experts said addressing the issues raised in the scathing FDA inspection report could take months.

Neither J&J nor the FDA has said when they expect vaccine production to resume at the Baltimore plant owned by Emergent Biosolutions Inc. Only one plant, in the Netherlands, is currently producing the key drug substance used in J&J's vaccine, the company said.

"It may take many months to make these changes," said Prashant Yadav, a global healthcare supply-chain expert at the Center for Global Development. He described some of the issues raised by the FDA as "quite significant."

J&J said it would ensure that all of the FDA issues are addressed promptly and comprehensively.

The 12-page report described dirty facilities and many instances of potential contamination. In some cases, employees carrying unsealed medical waste collided with containers used to make material for vaccines, it noted, adding that containers had been spotted elsewhere with cracks.

Problems were not investigated and cleanups were superficial, it added. In one example, a worker moved between rooms where different materials were being made on 19 different days while only documenting a single required shower, the report said.

FDA inspectors said the facility was not large enough, describing crowded rooms difficult to walk through without bumping into containers of materials and small doors that forced workers to push containers on the ground rather than use machines to carry them.

"Paint flecks were observed on the floor all along the sides of these walls" on corridors surrounding the manufacturing room and in a room were vials were filled, it said in one section, adding that there was "brown residue" on the wall and "black residue" on the floor in one plant room.

The investigation confirmed media reports that J&J shots made at the Emergent plant had been contaminated with material used to make vaccine for AstraZeneca. At the time, workers responded to the mix up with little more than a routine cleaning, it noted.

Millions of J&J doses were ruined, the New York Times reported. Production of AstraZeneca's vaccine was moved elsewhere.

"There is no assurance that other batches have not been subject to cross-contamination," the report said.

J&J has drawn scrutiny for months over its halting process to scale up production of the one-shot vaccine that is easier to handle and use than other authorized vaccines.

Its use in the United States has been paused since last week as health officials study a possible link to a very rare but serious blood clot condition.

Emergent has been seeking regulatory authorization to make the J&J vaccine in the United States. It stopped production at the plant recently, saying the FDA had asked it to do so after an inspection.

"What's important is that the FDA caught these deficiencies" and took steps to ensure the vaccine produced there was not used, said vaccine researcher Dr. Anna Durbin of Johns Hopkins University in Baltimore.

"Emergent has some work to do to clean up their process. They will likely need to be re-inspected by the FDA before any vaccine produced there would be accepted," she said.

Johnson & Johnson reiterated on Wednesday that it was working to establish a global supply chain in which 10 manufacturing sites would be involved in production of its COVID-19 vaccine, in addition the Netherlands plant.

The company has a U.S. government-brokered agreement with rival drugmaker Merck & Co, which is preparing to make doses of J&J's vaccine.


The inspection report said the FDA team had reviewed security camera footage in addition to an in-person site visit to the Emergent plant.

It found failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson and AstraZeneca.

Earlier this week, the U.S. House Representatives launched an investigation into whether Emergent used its relationship with a Trump administration official to get a vaccine manufacturing contract despite a record of not delivering on contracts.

Emergent said in a statement that it is working with the FDA and J&J to quickly resolve the issues outlined in the report.

The inspection, carried out between April 12 and April 20, also noted that Emergent did not produce adequate reports showing that the vaccines it was producing met quality standards.

J&J said it was redoubling its efforts to get authorization for the facility as quickly as possible.

J&J's oversight could help Emergent better address the FDA's concerns, none of which are especially difficult to fix, Cantor Fitzgerald analyst Brandon Folkes said in a note.

No vaccine manufactured at the Baltimore plant has been distributed for use in the United States.

(Reporting by Manas Mishra and Ankur Banerjee in Bengaluru; Carl O'Donnell in New York and Julie Steenhuysen in Chicago; Editing by Caroline Humer, Peter Henderson and Bill Berkrot)

By Carl O'Donnell and Julie Steenhuysen

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.44% 7930 Delayed Quote.7.80%
THE NEW YORK TIMES COMPANY 1.41% 43.2 Delayed Quote.-17.06%
All news about ASTRAZENECA PLC
12:18pFTSE : 100 flat as Vodafone loss offsets gains in banks; Oxford Biomedica shi..
11:44aASTRAZENECA  : Transaction by Person Discharging Managerial Responsibilities (Fo..
11:00aSpanish Study Shows Using Pfizer-BioNTech's COVID-19 Jab After One AstraZenec..
10:06aASTRAZENECA  : Nigeria's Biggest Challenge Is Vaccinating As Many People As Quic..
09:24aSteep Covid-19 Rise in Nepal Mirrors India's Surge
09:23aASTRAZENECA  : India's Serum Institute to start export of COVID-19 vaccine by ye..
07:31aASTRAZENECA  : Spanish study finds AstraZeneca vaccine followed by Pfizer dose i..
07:20aUK Study Shows Antibody Development In 96% People After One Dose of Pfizer/Bi..
05:59aASTRAZENECA  : Spanish study finds AstraZeneca vaccine followed by Pfizer dose i..
05:47aOXFORD BIOMEDICA  : Lifts 2021 Revenue Guidance as AstraZeneca Asks for More COV..
More news
Financials (USD)
Sales 2021 31 079 M - -
Net income 2021 4 531 M - -
Net Debt 2021 10 883 M - -
P/E ratio 2021 32,4x
Yield 2021 2,55%
Capitalization 147 B 146 B -
EV / Sales 2021 5,07x
EV / Sales 2022 4,50x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 130,52 $
Last Close Price 111,69 $
Spread / Highest target 48,6%
Spread / Average Target 16,9%
Spread / Lowest Target -13,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.16%448 704
ROCHE HOLDING AG-1.39%292 944
PFIZER, INC.8.54%224 524
ABBVIE INC.8.75%206 454
MERCK & CO., INC.-3.15%202 236